TDs call on pharma company to work with HSE to give access to life-changing drug Skyclarys
TheJournal.ieThe HSE has refused to fund the drug, which costs €288,000 per patient per year.
TheJournal.ie
TheJournal.ieThe HSE has refused to fund the drug, which costs €288,000 per patient per year.